The introduction of immune checkpoint inhibitors highly impacted the treatment landscape of melanoma over the last decade. At ESMO 2019, several abstracts again proved the clinical potential of these agents in the treatment of melanoma, both in (neo)adjuvant as in the advanced setting. In addition to this, promising results were presented with talimogene laherparepvec in early and in metastatic melanoma. Finally, several abstracts also discussed combinations of targeted agents and immunotherapy in patients with advanced melanoma.